An inhibitor of the catalytic site of mTOR, inhibiting both mTORC1 and mTORC2 (IC<sub>50</sub>s = 22 and 65 nM, respectively) prohibits proliferation, induces autophagy, and potentiates apoptosis in BCR-ABL transformed cells and other cancer cells
An inhibitor of the catalytic site of mTOR, inhibiting both mTORC1 and mTORC2 (IC<sub>50</sub>s = 22 and 65 nM, respectively) prohibits proliferation, induces autophagy, and potentiates apoptosis in BCR-ABL transformed cells and other cancer cells
A selective TRPA1 blocker that antagonizes TRPA1-mediated calcium influx induced by allyl isothiocyanate and 4-hydroxy nonenal (IC<sub>50</sub>s = 14.3 and 18.
A selective TRPA1 blocker that antagonizes TRPA1-mediated calcium influx induced by allyl isothiocyanate and 4-hydroxy nonenal (IC<sub>50</sub>s = 14.3 and 18.
2-Methoxyestradiol (2-ME2) is a natural metabolite of estradiol with potent antitumor and antiangiogenic properties. 2-Methoxyestradiol is a natural metabolite of estradiol with potent antitumor and antiangiogenic properties.
2-Methoxyestradiol (2-ME2) is a natural metabolite of estradiol with potent antitumor and antiangiogenic properties. 2-Methoxyestradiol is a natural metabolite of estradiol with potent antitumor and antiangiogenic properties.
A synthetic CMR1/TRPM8 super agonist that is 2.5-fold more efficacious and nearly 200-fold more potent than the reference cold thermosensory agonist, l-menthol.
A synthetic CMR1/TRPM8 super agonist that is 2.5-fold more efficacious and nearly 200-fold more potent than the reference cold thermosensory agonist, l-menthol.
A selective TRPA1 blocker that antagonizes TRPA1-mediated calcium influx induced by allyl isothiocyanate and 4-hydroxy nonenal (IC<sub>50</sub>s = 14.3 and 18.
A selective TRPA1 blocker that antagonizes TRPA1-mediated calcium influx induced by allyl isothiocyanate and 4-hydroxy nonenal (IC<sub>50</sub>s = 14.3 and 18.
An inhibitor of PHGDH, inhibiting serine synthesis from 3-PG in cells (IC<sub>50</sub> = 33 µM) inhibits the proliferation of cancer cells by blocking de novo serine synthesis.
An inhibitor of PHGDH, inhibiting serine synthesis from 3-PG in cells (IC<sub>50</sub> = 33 µM) inhibits the proliferation of cancer cells by blocking de novo serine synthesis.
An inhibitor of the catalytic site of mTOR, inhibiting both mTORC1 and mTORC2 (IC<sub>50</sub>s = 22 and 65 nM, respectively) prohibits proliferation, induces autophagy, and potentiates apoptosis in BCR-ABL transformed cells and other cancer cells
An inhibitor of the catalytic site of mTOR, inhibiting both mTORC1 and mTORC2 (IC<sub>50</sub>s = 22 and 65 nM, respectively) prohibits proliferation, induces autophagy, and potentiates apoptosis in BCR-ABL transformed cells and other cancer cells
An antagonist of OX2R (pKi = 7.5) that exhibits >250-fold selectivity for hOX2R compared with OX1R (IC<sub>50</sub>s = 40 nM and >10,000 nM, respectively.
An antagonist of OX2R (pKi = 7.5) that exhibits >250-fold selectivity for hOX2R compared with OX1R (IC<sub>50</sub>s = 40 nM and >10,000 nM, respectively.
A selective TRPA1 blocker that antagonizes TRPA1-mediated calcium influx induced by allyl isothiocyanate and 4-hydroxy nonenal (IC<sub>50</sub>s = 14.3 and 18.
A selective TRPA1 blocker that antagonizes TRPA1-mediated calcium influx induced by allyl isothiocyanate and 4-hydroxy nonenal (IC<sub>50</sub>s = 14.3 and 18.
A dual antagonist of both OX1R and OX2R (Kis = 0.2 and 3 nM, respectively) that demonstrates good brain penetration when administered intraperitoneally promotes sleep, prevents drug-induced plasticity and drug relapse, and decreases fear and
A dual antagonist of both OX1R and OX2R (Kis = 0.2 and 3 nM, respectively) that demonstrates good brain penetration when administered intraperitoneally promotes sleep, prevents drug-induced plasticity and drug relapse, and decreases fear and